Introduction: Insulin analogues were developed to improve treatment of insulin-treated diabetes with respect to glycemic control and avoidance of hypoglycemic episodes. Short-acting insulin analogues (aspart, lispro and glulisine) were designed to mimic the fast physiological postprandial insulin release and long-acting insulin analogues (detemir and glargine) were designed to mimic the basal continuous insulin release with minimal peak action, thereby leading to a presumed decreased risk of hypoglycemia. Objectives: To compare the frequency of hypoglycemia between combination of insulin detemir and aspart with combination of NPH and regular insulin in patients of type 1 diabetes mellitus. Study Design: Randomized controlled trial.Setting...
CONTEXT: Among the growing population of individuals with type 2 diabetes mellitus, many patients ar...
[english] Objective: There is currently a lack of evidence from direct comparisons of treatment outc...
This randomised (1: 1), multinational, open-labelled, parallel group trial compared insulin detemir ...
Introduction: Among the various types of insulin analogs, some are long acting and some are short ac...
Aims This 52-week, randomized, multinational, open-label, parallel-group, non-inferiority trial inve...
Aims This 52-week, randomized, multinational, open-label, parallel-group, non-inferiority trial inve...
OBJECTIVE — Insulin detemir is a soluble basal insulin analog with a unique mechanism of protracted ...
Aims: This 24-month, multi-national, open-label, parallel group trial investigated the long-term eff...
OBJECTIVE — Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the l...
BACKGROUND: Injection of long-acting insulin at bedtime is a common therapeutic approach for patient...
Aim: To perform a network meta-analysis between long-acting insulin analogues (glargine and detemi...
BACKGROUND: Injection of long-acting insulin at bedtime is a common therapeutic approach for patient...
Aim: To perform a network meta-analysis between long-acting insulin analogues (glargine and detemi...
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the lim...
P>AimsThe efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin det...
CONTEXT: Among the growing population of individuals with type 2 diabetes mellitus, many patients ar...
[english] Objective: There is currently a lack of evidence from direct comparisons of treatment outc...
This randomised (1: 1), multinational, open-labelled, parallel group trial compared insulin detemir ...
Introduction: Among the various types of insulin analogs, some are long acting and some are short ac...
Aims This 52-week, randomized, multinational, open-label, parallel-group, non-inferiority trial inve...
Aims This 52-week, randomized, multinational, open-label, parallel-group, non-inferiority trial inve...
OBJECTIVE — Insulin detemir is a soluble basal insulin analog with a unique mechanism of protracted ...
Aims: This 24-month, multi-national, open-label, parallel group trial investigated the long-term eff...
OBJECTIVE — Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the l...
BACKGROUND: Injection of long-acting insulin at bedtime is a common therapeutic approach for patient...
Aim: To perform a network meta-analysis between long-acting insulin analogues (glargine and detemi...
BACKGROUND: Injection of long-acting insulin at bedtime is a common therapeutic approach for patient...
Aim: To perform a network meta-analysis between long-acting insulin analogues (glargine and detemi...
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the lim...
P>AimsThe efficacy of two basal insulins, insulin lispro protamine suspension (ILPS) and insulin det...
CONTEXT: Among the growing population of individuals with type 2 diabetes mellitus, many patients ar...
[english] Objective: There is currently a lack of evidence from direct comparisons of treatment outc...
This randomised (1: 1), multinational, open-labelled, parallel group trial compared insulin detemir ...